The Cheapest Grant Application in Federal Science Closes September 19 — and It Decides What the NIH Common Fund Funds for the Next Decade

Most researchers ignore Requests for Information. They are unfunded, ungraded, and easy to file under "someone else's job." That instinct is usually right and is badly wrong about this one.

NOT-RM-26-004, released July 21, 2026, asks the public to tell the NIH Common Fund what biomedical and behavioral research challenges deserve a cross-institute program. Responses are due at 11:59:59 pm ET on September 19, 2026 — a Saturday, which in practice means your submission needs to be done by Friday the 18th unless you enjoy weekend portal roulette. Submission runs through a single web form at rfi.grants.nih.gov. There is no budget justification, no biosketch, no letters of support, and no page limit beyond NIH's request that you keep it concise. Responses may be submitted anonymously.

This is the front door to the only pot of NIH money whose entire purpose is to fund things no individual institute will fund alone. And it is the front door in a year when that pot got dramatically smaller.

The number that changes how you should read this RFI

The FY 2026 budget request for the Common Fund was $347.4 million — a decrease of $337.6 million, or 49.3 percent, from the FY 2025 enacted level.

Hold that against what the Common Fund normally does. Its programs are, by design, 10-year commitments that spin up dozens of awards across multiple institutes and produce durable community resources — the Human BioMolecular Atlas Program, 4D Nucleome, Bridge to Artificial Intelligence, Somatic Cell Genome Editing, the High-Risk High-Reward portfolio. Roughly two dozen programs are active at any moment, and each one is consuming its slice of the fund on a multi-year obligation schedule that does not flex much when the top line moves.

A halved request against a portfolio of standing multi-year commitments means new-program capacity is the variable that absorbs the hit. The practical consequence for anyone answering this RFI: the bar for "worth starting in the current environment" is meaningfully higher than it was in the 2022 or 2023 idea cycles, and ideas that read as expensive infrastructure builds will compete against ideas that read as leverage — things that make existing Common Fund data assets, or existing institute portfolios, worth more without a new construction project underneath them.

That is not a reason to self-censor an ambitious idea. It is a reason to say out loud, in your response, what the idea makes cheaper or faster for everyone else.

The five criteria are not boilerplate

Every Common Fund investment since the program's creation has had to satisfy the same five tests, and the RFI restates them verbatim. Read them as a scoring rubric, because that is functionally what they are:

• Transformative — strong potential for exceptionally high and broadly applicable impact in biomedical or behavioral research.
• Catalytic — time-limited investments of 10 years or less, designed to capitalize on new knowledge or breakthroughs to accelerate subsequent research.
• Goal-driven — defined goals producing specific deliverables: new knowledge, data sets, resources, methods, or technologies.
• Synergistic — advances the missions of multiple NIH Institutes, Centers, and Offices, leverages expertise from multiple ICOs, and accelerates research relevant to multiple diseases and conditions.
• Novel — pursues innovative solutions to challenges important to the NIH mission that no other entity is likely or able to address.

Two of those five kill most submissions on contact.

Catalytic means the program has to end. A proposal that describes a permanent capability — an ongoing service, a facility that needs indefinite operating support, a registry someone has to maintain forever — fails the criterion no matter how valuable it is. The Common Fund's model is: build the thing, hand it to the community and to the institutes, exit. If your idea has no exit, it belongs somewhere else in NIH.

Novel, as written, is a test of counterfactual necessity, not of scientific excitement. "No other entity is likely or able to address" excludes work that a single institute would plausibly fund, that industry is already racing toward, or that a foundation has staked out. If NCI would obviously do this, NCI should do this. The Common Fund exists for the orphaned middle — the problem that is everyone's and therefore no one's.

Synergistic is the one you can actively engineer in a response. An idea framed as "cancer needs X" reads as an NCI request. The same idea framed as "cancer, neurodegeneration, and autoimmunity all stall at the same measurement gap, and X closes it for all three" reads as a Common Fund program. The science does not change. The classification does.

What is new in the 2026 version

NIH runs this RFI on a near-annual cadence — NOT-RM-22-016, NOT-RM-23-013, NOT-RM-24-001, NOT-RM-24-010 are its recent predecessors — and the version-to-version deltas are where the signal lives.

Two bullets in the 2026 solicitation did not exist in the earlier ones.

First, a small-lab burden bullet. NIH explicitly invites ideas about "critical challenges that small labs or research groups face with respect to funding, contracting, or navigating the regulatory landscape." That is a remarkable thing to find in a scientific-ideas RFI. It is not asking for a discovery; it is asking what is structurally broken about being a small research group in 2026. If you have ever lost a quarter to an IRB reciprocity problem, a materials transfer agreement, a subaward that took seven months to execute, or a data use agreement that outlived the postdoc who needed the data — that is a submittable response. Common Fund's "re-engineering the research enterprise" category exists precisely for programs of this shape, and this bullet is an unusually direct invitation to populate it.

Second, explicit alignment to two policy documents. The RFI asks respondents to consider priorities from Advancing NIH's Mission Through a Unified Strategy and the Make Our Children Healthy Again Strategy. The unified strategy was announced August 15, 2025, and the unified funding framework it created took effect with the Council of Councils meeting on January 29, 2026. Its stated emphases include chronic disease, chronic childhood conditions and nutrition, next-generation tools such as artificial intelligence and alternative testing models, real-world data platforms, replication and reproducibility, and biomedical workforce training.

You do not have to like this framing to use it accurately. An RFI response is not a policy comment; it is an attempt to get an idea in front of the staff who will draft the next slate of concept proposals. If your idea genuinely intersects chronic disease mechanisms, pediatric health, reproducibility infrastructure, or non-animal testing models, name the intersection in plain language. If it does not, do not manufacture one — staff read hundreds of these, and a forced tie-in reads exactly as forced.

How to write a response that actually lands

NIH asks for concise ideas focused on broad concepts rather than detailed descriptions. Take that literally. The failure mode is submitting an abridged R01.

A structure that maps cleanly onto the five criteria:

1. The challenge or emerging opportunity, in two or three sentences, stated so a program officer outside your field can repeat it back correctly.
2. What is missing — the resource, tool, dataset, method, or knowledge that does not exist. Be concrete about the deliverable. "A benchmarked reference dataset covering X across Y conditions" beats "better understanding of X."
3. Why now — the specific advance, technology, or cost curve that makes this tractable in 2026 and not in 2021. Timeliness is an explicit ask in the RFI and it is where most responses are vaguest.
4. Who else it helps — name the institutes and disease areas, plural. This is your synergy argument and it should be unmissable.
5. What is done in 5 to 10 years — the RFI asks you to consider "completed work products that could be accomplished in 5-10 years." Write the end state. A program that cannot describe its own finish line fails the catalytic test.
6. Impact on human health, stated without inflation.

One page is plenty. Two is the ceiling.

A few tactical notes. Responses may be used publicly — in reports, in state-of-the-science summaries, in future funding announcements — so submit nothing you would not want quoted, and nothing you have not protected. Do not include preliminary data you intend to build a grant around. Conversely, the public-use clause is exactly why a well-written response is worth the hour: NIH reserves the right to reuse the language, which means a crisply stated framing has a real chance of surviving into a concept document with its shape intact.

Coordinate, but do not astroturf. A scientific society or consortium submitting one strong, jointly authored idea is more useful than fifteen members submitting fifteen near-identical paragraphs. The Office of Strategic Coordination is looking for coherent problems, not vote counts.

Why an hour on this beats an hour on almost anything else

The economics here are unusual. A Common Fund program that emerges from an idea cycle typically distributes tens to hundreds of millions of dollars across many awards, many institutions, and up to a decade. The application cost of putting an idea into that pipeline is one page and no budget.

The catch is that the pipeline is slow and indirect. Ideas submitted this month may inform a workshop in 2027, a pilot initiative after that, and a program some years later — or nothing at all. NIH says plainly that the RFI is for information and planning only, creates no obligation, and will not pay for preparation. Nobody should trade a near-term application deadline for this.

But the fall calendar is thick with deadlines that thousands of labs are chasing against known odds, and thin with chances to influence what gets funded at all. This is the second kind, it costs an hour, and it closes September 19. Finding the handful of opportunities where your specific work has genuine leverage — rather than the hundreds where it is one of nine hundred applications — is the whole problem Granted exists to shorten.

Sources: NOT-RM-26-004 (NIH Guide) · NIH Common Fund FY 2026 Congressional Justification · Advancing NIH's Mission Through a Unified Strategy · NIH Common Fund programs